Status:
COMPLETED
Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section
Lead Sponsor:
Talkha Central Hospital
Collaborating Sponsors:
Al-Azhar University
Conditions:
Hemorrhage of Cesarean Section and/or Perineal Wound
Postpartum Hemorrhage
Eligibility:
FEMALE
20-40 years
Phase:
PHASE4
Brief Summary
This study aims to define a safe prophylactic intravenous TXA dose with an advantage over others in reducing total blood loss volume at secondary uncomplicated LSCS.
Detailed Description
Bleeding during vaginal or operative delivery is always of prime concern. Despite significant progress in obstetric care 125,000 women die from obstetric hemorrhage annually in the world. The inciden...
Eligibility Criteria
Inclusion
- Maternal average age of 20-40 years.
- Singleton pregnancy at term between 38±5 days and 40 weeks.
- Elective planned or emergency secondary lower segment caesarean sections (LSCS).
Exclusion
- Women with severe medical and surgical complications as any of the following will be excluded :
- Heart, liver, kidney, or brain diseases, and blood disorders.
- Abruptio placenta, and placental abnormalities or accrete syndromes.
- Polyhydramnios, macrosomia, preeclampsia, or allergy to tranexamic acid.
- History of thromboembolic disorders, or severe anemia.
Key Trial Info
Start Date :
April 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02739815
Start Date
April 1 2016
End Date
June 1 2016
Last Update
June 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University, Faculty of Medicine for Boys ( Cairo ), Al-Hussein University Hospital
Cairo, Cairo Governorate, Egypt